Katayama Syndrome After Lake Malawi: Treat the Worms That Aren't Grown Yet, or Wait
A college student develops classic Katayama syndrome five weeks after swimming in Lake Malawi — fever, urticarial rash, hepatosplenomegaly, marked eosinophilia. Praziquantel is the right drug eventually, but it doesn't reliably kill the immature schistosomula still migrating at this stage. The question is whether to treat now anyway, or wait for a single dose more likely to work.
J.L., a 22-year-old college student, spent her last week of a semester abroad in southern Africa doing exactly what the pre-departure health briefing had told her not to: swimming in Lake Malawi with a group of new friends on an afternoon too beautiful to pass up, freshwater warnings shrugged off the way most 22-year-olds shrug off warnings that sound abstract until they aren't. She's been backpacking through Zambia and Botswana in the five weeks since, staying loosely in touch with her parents and mostly off any predictable schedule, which is part of why this visit — arranged through a cousin who happens to work at the clinic — almost didn't happen before her flight home next week.
The fever started four days ago, alongside an itchy, migrating urticarial rash and a headache she'd initially blamed on dehydration. On exam she has mild hepatosplenomegaly and a striking eosinophil count — 18% of a leukocytosis that's otherwise unremarkable — and taken together with the freshwater exposure and the five-week timeline, this reads as a textbook case of Katayama syndrome, the acute hypersensitivity reaction that follows early schistosome infection. The complicating fact, the one actually driving today's conversation, is that praziquantel — the only real antihelminthic option for schistosomiasis — is substantially less effective against the immature schistosomula still migrating through her tissues at five weeks than it is against fully matured adult worms, a distinction Ross and colleagues set out in their New England Journal review of schistosomiasis more than two decades ago and that has not been overturned since. Whatever gets decided today has to weigh that reduced efficacy against a traveler who is leaving the country in a week, with no guarantee she'll reliably return for a second dose once the worms have had time to mature — a scheduling reality that turns out to matter as much to today's decision as the underlying pharmacology does.
A drug that works better than it will today
I'd treat with praziquantel today. Yes, it's less effective against the immature schistosomula she's carrying at five weeks than it will be once they've matured — but "less effective" isn't "ineffective," and she's flying home in a week with a travel pattern that hasn't exactly been predictable so far this semester. A partial benefit she actually receives beats a full benefit she may never come back for.
I'd pair it with a short corticosteroid course for the hypersensitivity symptoms regardless of which timing position wins — that part isn't really in dispute.
The efficacy gap against schistosomula isn't a minor caveat, it's the reason Ross and colleagues' review recommends waiting until worms have matured — giving the drug now risks both under-treating and, in principle, triggering a sharper hypersensitivity flare as whatever organisms it does kill release more antigen into a system already reacting to this infection.
I hear the follow-up concern, and it's real. But treating her today mainly to avoid a scheduling problem isn't the same as treating her today because it's the better medical decision — those are two different justifications, and I don't think the second one holds up here.
I don't think this actually has to be a now-versus-later choice anymore. CDC's own Yellow Book guidance has moved toward treating at diagnosis AND repeating the dose at six to eight weeks, specifically because the loss-to-follow-up problem is real and common enough that a deferred-only strategy keeps failing in practice, not because anyone decided the efficacy concern wasn't real.
Treat her today, for the partial benefit and the symptom relief, and build the six-to-eight-week dose into her discharge plan as a scheduled requirement, not a suggestion — that resolves both of your concerns without asking either of you to concede the underlying pharmacology.
Agreed: praziquantel given today alongside a short corticosteroid course for symptom control, with a mandatory repeat dose scheduled at six to eight weeks and built directly into her discharge paperwork rather than left as a verbal recommendation, given her travel pattern.
The travel medicine physician's efficacy concern was not dismissed — it's the reason the second dose is mandatory rather than optional, not a formality. All three voices ended aligned on the two-dose plan once it was framed as resolving the follow-up risk without abandoning the underlying pharmacology either physician had raised.